Javascript must be enabled to continue!
FRI637 Missed MODY With Complex Mutation
View through CrossRef
Abstract
Disclosure: S. Bulchandani: None. S. Majety: None. P. Kundra: None.
Introduction: The prevalence range of Maturity-Onset Diabetes of the Young (MODY) is 1-5% among all patients diagnosed with diabetes. Strong family history of diabetes is suggestive of autosomal dominant inheritance. The symptoms of MODY range from mild asymptomatic hyperglycemia to overt insulinopenia requiring insulin therapy. Clinical Case: 33-year-old male presented to the endocrinology clinic for evaluation. He was diagnosed with type 2 diabetes mellitus at the age of 13 years and was initially treated with insulin which was subsequently transitioned to repaglinide and metformin. Reported history of hypoglycemia at birth in self and recently born daughter. Family History was significant for diabetes mellitus diagnosed in biological father at the age of 16 years. Genetic testing for monogenic diabetes revealed pathogenic variant in hepatocyte nuclear factor 4 alpha (HNF4a) and variant of unknown significance in Paired Box Gene 4 (PAX4). Therapy was switched to glipizide 2.5 mg orally which resulted in adequate glycemic control. Genetic testing was recommended for his daughter. Conclusion: MODY is a rare condition and because of its wide clinical presentation, it is common for it to be missed. There are about 14 subtypes of MODY with different genetic mutations, each affecting the beta cell function in a different way. Our case is unique given that our patient had two genetic mutations. Amongst all forms of MODY, HNF4a with a prevalence of 5% to 10% is the third most common mutation of MODY. PAX4 is a transcription factor that is critical for the formation of beta cells, and is important as a regulator in commitment of progenitor cells to mature islet cells. Mutations in PAX gene associated with monogenic diabetes were first identified in two patients of Thai origin, who did not present with mutations in the other known MODY genes. There should be high vigilance and low threshold for genetic testing for MODY in patients who have high likelihood of possessing a form of MODY, particularly as the treatment can be tailored to the clinical presentation of the patient. References: 1. Abreu GM, Soares CAPD, Tarantino RM, da Fonseca ACP, de Souza RB, Pereira MFC, Cabello PH, Rodacki M, Zajdenverg L, Zembrzuski VM, Campos Junior M. Identification of the First PAX4-MODY Family Reported in Brazil. Diabetes Metab Syndr Obes. 2020 Jul 24; 13:2623-2631. doi: 10.2147/DMSO.S256858. PMID: 32801813; PMCID: PMC7399458. 2. Antal Z. Maturity-Onset Diabetes of the Young (MODY): Genetic Causes, Clinical Characteristics, Considerations for Testing, and Treatment Options. Endocrines. 2021; 2(4):485-501. https://doi.org/10.3390/endocrines2040043
Presentation: Friday, June 16, 2023
The Endocrine Society
Title: FRI637 Missed MODY With Complex Mutation
Description:
Abstract
Disclosure: S.
Bulchandani: None.
S.
Majety: None.
P.
Kundra: None.
Introduction: The prevalence range of Maturity-Onset Diabetes of the Young (MODY) is 1-5% among all patients diagnosed with diabetes.
Strong family history of diabetes is suggestive of autosomal dominant inheritance.
The symptoms of MODY range from mild asymptomatic hyperglycemia to overt insulinopenia requiring insulin therapy.
Clinical Case: 33-year-old male presented to the endocrinology clinic for evaluation.
He was diagnosed with type 2 diabetes mellitus at the age of 13 years and was initially treated with insulin which was subsequently transitioned to repaglinide and metformin.
Reported history of hypoglycemia at birth in self and recently born daughter.
Family History was significant for diabetes mellitus diagnosed in biological father at the age of 16 years.
Genetic testing for monogenic diabetes revealed pathogenic variant in hepatocyte nuclear factor 4 alpha (HNF4a) and variant of unknown significance in Paired Box Gene 4 (PAX4).
Therapy was switched to glipizide 2.
5 mg orally which resulted in adequate glycemic control.
Genetic testing was recommended for his daughter.
Conclusion: MODY is a rare condition and because of its wide clinical presentation, it is common for it to be missed.
There are about 14 subtypes of MODY with different genetic mutations, each affecting the beta cell function in a different way.
Our case is unique given that our patient had two genetic mutations.
Amongst all forms of MODY, HNF4a with a prevalence of 5% to 10% is the third most common mutation of MODY.
PAX4 is a transcription factor that is critical for the formation of beta cells, and is important as a regulator in commitment of progenitor cells to mature islet cells.
Mutations in PAX gene associated with monogenic diabetes were first identified in two patients of Thai origin, who did not present with mutations in the other known MODY genes.
There should be high vigilance and low threshold for genetic testing for MODY in patients who have high likelihood of possessing a form of MODY, particularly as the treatment can be tailored to the clinical presentation of the patient.
References: 1.
Abreu GM, Soares CAPD, Tarantino RM, da Fonseca ACP, de Souza RB, Pereira MFC, Cabello PH, Rodacki M, Zajdenverg L, Zembrzuski VM, Campos Junior M.
Identification of the First PAX4-MODY Family Reported in Brazil.
Diabetes Metab Syndr Obes.
2020 Jul 24; 13:2623-2631.
doi: 10.
2147/DMSO.
S256858.
PMID: 32801813; PMCID: PMC7399458.
2.
Antal Z.
Maturity-Onset Diabetes of the Young (MODY): Genetic Causes, Clinical Characteristics, Considerations for Testing, and Treatment Options.
Endocrines.
2021; 2(4):485-501.
https://doi.
org/10.
3390/endocrines2040043
Presentation: Friday, June 16, 2023.
Related Results
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY)
The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY)
AbstractBackgroundThe most common type of monogenic diabetes is maturity-onset diabetes of the young (MODY), a clinically and genetically heterogeneous group of endocrine disorders...
Maturity Onset Diabetes of the Young (MODY) : Diagnosa dan Tatalaksana
Maturity Onset Diabetes of the Young (MODY) : Diagnosa dan Tatalaksana
Maturity Onset Diabetes of the Young (MODY), merupakan salah satu bentuk dari defek sel beta pankreas akibat mutasi genetik. Hingga saat ini terdapat lebih dari 10 mutasi fenotip g...
Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A‐MODY) and MODY 3 (HNF1A‐MODY)?
Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A‐MODY) and MODY 3 (HNF1A‐MODY)?
AbstractAims Genetic testing is needed for the formal diagnosis of maturity‐onset diabetes of the young (MODY), but this is not widely available. If any MODY biomarkers were known...
Identification Of Pathogenic Mutations And Application Of Polygenic Risk Scores To Differentiate MODY Patients From Other Diabetes Types
Identification Of Pathogenic Mutations And Application Of Polygenic Risk Scores To Differentiate MODY Patients From Other Diabetes Types
Abstract
Maturity-onset Diabetes of the Young (MODY) presents a diagnostic challenge, with a large proportion of cases lacking identifiable genetic mutations. This study in...
Glucokinase-Related Maturity-Onset Diabetes of the Young in India and the Clinical Utility of the MODY Probability Calculator for Identifying Underdiagnosed and Rare Forms
Glucokinase-Related Maturity-Onset Diabetes of the Young in India and the Clinical Utility of the MODY Probability Calculator for Identifying Underdiagnosed and Rare Forms
Abstract
Aims/Introduction:
Heterozygous inactivating mutations in the glucokinase (GCK) gene induce a fasting hyperglycaemic disorder known as ...
Meglitinide Analogues in Adolescent Patients With HNF1A-MODY (MODY 3)
Meglitinide Analogues in Adolescent Patients With HNF1A-MODY (MODY 3)
For pediatric patients with hepatocyte nuclear factor-1A (HNF1A)–maturity-onset diabetes of the young (MODY 3), treatment with sulfonylureas is recommended. In adults with HNF1A-MO...
The MODY Masquerade
The MODY Masquerade
Introduction: Maturity Onset Diabetes of the Young (MODY) is a relatively uncommon, but increasingly recognized cause of diabetes. Many MODY patients are misdiagnosed as type 1 or ...

